Co-prevalence of other tumors in patients harboring pituitary tumors

Couldwell, William T.; Cannon‐Albright, Lisa A.

doi:10.3171/2014.8.jns132139

Cited by 12 publications

(7 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Co-occurrence of two or more brain tumors with different histological features is rare, although a few cases have been reported [26]. Moreover, in patients harboring pituitary tumors co-prevalence of other primary tumors is demonstrated to be significantly higher than expected in the general population [27]. Unfortunately, no material was available from the prolactinoma and hence only the cerebellar tumor (PA) from case PA3 was studied in the present paper.…”

Section: Resultsmentioning

confidence: 99%

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

et al. 2017

View full text Add to dashboard Cite

Pilocytic astrocytoma (PA) is the most common pediatric brain tumor. A recurrent feature of PA is deregulation of the mitogen activated protein kinase (MAPK) pathway most often through KIAA1549-BRAF fusion, but also by other BRAF- or RAF1-gene fusions and point mutations (e.g. BRAFV600E). These features may serve as diagnostic and prognostic markers, and also facilitate development of targeted therapy. The aims of this study were to characterize the genetic alterations underlying the development of PA in six tumor cases, and evaluate methods for fusion oncogene detection. Using a combined analysis of RNA sequencing and copy number variation data we identified a new BRAF fusion involving the 5’ gene fusion partner GTF2I (7q11.23), not previously described in PA. The new GTF2I-BRAF 19–10 fusion was found in one case, while the other five cases harbored the frequent KIAA1549-BRAF 16–9 fusion gene. Similar to other BRAF fusions, the GTF2I-BRAF fusion retains an intact BRAF kinase domain while the inhibitory N-terminal domain is lost. Functional studies on GTF2I-BRAF showed elevated MAPK pathway activation compared to BRAFWT. Comparing fusion detection methods, we found Fluorescence in situ hybridization with BRAF break apart probe as the most sensitive method for detection of different BRAF rearrangements (GTF2I-BRAF and KIAA1549-BRAF). Our finding of a new BRAF fusion in PA further emphasis the important role of B-Raf in tumorigenesis of these tumor types. Moreover, the consistency and growing list of BRAF/RAF gene fusions suggests these rearrangements to be informative tumor markers in molecular diagnostics, which could guide future treatment strategies.

show abstract

Section: Resultsmentioning

confidence: 99%

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Our case represents a unique case of a coincident pituitary adenoma and sellar meningioma at time of initial presentation and within the same surgical specimen. As we recently described, there is a plethora of tumors that can co-occur with pituitary tumors [1]. The impressive diversity of this pathology should be a consideration during the treatment of patients with lesions in the sellar region.…”

mentioning

confidence: 85%

Authors’ reply to letter to the editor regarding “Coincident pituitary adenoma and sellar meningioma”

2015

Self Cite

View full text Add to dashboard Cite

“…For example, previous research on intraductal papillary mucinous neoplasms (IPMNs) has shown that patients with IPMNs have a higher risk for concomitant extrapancreatic neoplasms in the absence of any syndromic diagnosis [2–4]. Similarly, patients with adrenal incidentalomas have been observed to have a higher prevalence of thyroid nodules [5], and patients with pituitary adenomas may be at a higher risk for developing primary tumors at other sites [6–11]. Data from the nationwide Swedish Family-Cancer Database which examined the risk of subsequent primary neoplasms after the occurrence of an endocrine gland tumor [12] found that the risk for a second endocrine tumor was substantially higher following the first [12]; thereby, suggesting that the development of a benign endocrine tumor may increase the likelihood of developing subsequent tumors [12].…”

Section: Introductionmentioning

confidence: 99%

Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia

Hao

Luque-Fernandez

López

et al. 2019

International Journal of Endocrinology

View full text Add to dashboard Cite

Context Patients with adrenocortical tumors have been frequently observed to have nonadrenal neoplasia. Objective To investigate whether patients with benign adrenocortical tumors have a higher likelihood of having nonadrenal neoplasia detected. Design and Participants Case-control study of patients with benign adrenocortical tumors (cases; n = 400) and normal adrenal glands (controls; n = 400), who underwent repeated abdominal cross-sectional imaging. Main Outcomes Primary analyses: association between case-control status and benign abdominal neoplasia detected via cross-sectional imaging. Secondary analyses: association between case-control status and tumors detected via other imaging modalities. Results The mean interval of abdominal imaging was 4.7 (SD = 3.8) years for cases and 5.9 (4.8) years for controls. Cases were more likely to have detected intraductal papillary mucinous neoplasms (IPMNs) of the pancreas (8.5% vs. 4.5%, adjusted OR = 2.22, 95% CI (1.11, 4.63)) compared with controls. In secondary analyses, cases were more likely to have detected thyroid nodules (25.5% vs. 17.0%, adjusted OR = 1.77, 95% CI (1.15, 2.74)), hyperparathyroidism or parathyroid adenomas (3.5% vs. 1.3%, adjusted OR = 3.00, 95% CI (1.00, 11.64)), benign breast masses (6.0% vs. 3.3%, adjusted OR = 3.25, 95% CI (1.28, 8.78)), and benign prostatic hyperplasia (20.5% vs. 5.3%, adjusted OR = 3.20, 95% CI (1.14, 10.60)). Using a composite outcome, cases had higher odds of detection of the composite of IPMN, thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia (adjusted OR = 2.36, 95% CI: 1.60, 3.50) when compared with controls. Conclusions Patients with benign adrenocortical tumors had higher odds of detected pancreatic IPMN, as well as thyroid nodules, parathyroid tumors, benign breast masses, and prostate hyperplasia compared with patients with normal adrenal glands. These associations may have important implications for patient care and healthcare economics, regardless of whether they reflect incidental discoveries due to imaging detection or frequency bias, or a common risk for developing multiple neoplasia.

show abstract

Co-prevalence of other tumors in patients harboring pituitary tumors

Abstract: This information will prove useful for counseling patients in whom pituitary tumors have been diagnosed and suggests strong genetic or environmental co-risks for the development of other tumors.

Cited by 12 publications

References 13 publications

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

A new GTF2I-BRAF fusion mediating MAPK pathway activation in pilocytic astrocytoma

Authors’ reply to letter to the editor regarding “Coincident pituitary adenoma and sellar meningioma”

Benign Adrenocortical Tumors and the Detection of Nonadrenal Neoplasia

Contact Info

Product

Resources

About